(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected - 2Moving Pool Highlights for 2024
- 3Dozens of hidden star streams found in the outskirts of our Milky Way galaxy
- 4A somber Thor is returning for 'Avengers: Doomsday': Watch the dread-filled teaser
- 5Tech for Wellbeing: Applications and Devices for a Better You
- 'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- Figure out How to Forestall Tooth Staining
- Tributes pour in for James Ransone, 'The Wire' actor who died at 46
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- German finance minister seeks better market access in China talks
- Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- Changes to CDC website spark debate over autism and vaccine misinformation
